Because pluripotent embryonic stem cells (ESCs) are able to differentiate into any tissue, they are attractive agents for tissue regeneration. Although improvement of cardiac function has been observed after transplantation of pluripotent ESCs, the extent to which these effects reflect ESCmediated re-muscularization, re-vascularization or paracrine mechanisms is unknown. Moreover, because ESCs may generate teratomas, the ability to predict the outcome of cellular differentiation, especially when transplanting pluripotent ESCs, is essential; conversely, a requirement to use predifferentiated ESCs would limit their application to highly characterized subsets that are available in limited numbers. In the experiments reported here we transplanted low numbers of two murine ESC lines, respectively engineered to express a β-galactosidase gene from either a constitutive (elongation factor, EF) or a cardiac-specific (α-myosin heavy chain, α-MHC) promoter, into infarcted mouse myocardium. Although ESC-derived tumors formed within the pericardial space in 21% of injected hearts, lacZ histochemistry revealed that engraftment of ESC was restricted to the ischemic myocardium. Echocardiographic monitoring of ESC-injected hearts that did not form tumors revealed functional improvements by four weeks post-infarction, including significant increases in ejection fraction (EF), circumferential fiber shortening velocity (VCF) and peak mitral bloodflow velocity (peak-E). These experiments indicate that the infarcted myocardial environment can support engraftment and cardiomyogenic differentiation of pluripotent ESCs, concomitant with partial functional recovery.
Introduction
The potential of stem cells to regenerate adult tissues has caused extraordinary interest in their therapeutic application. Stem cells are classified as 'adult' or 'embryonic', according to their respective origins from within niches of mature adult tissues and bone marrow, or from blastocyst-stage embryos. The possibility that adult stem cells can repair infarcted myocardium was indicated in experiments using animal models (Quaini et al., 2002; Beltrami et al., 2003; Mangi et al., 2003) . Although initial results from trials in human patients using autologous bone marrow cells were encouraging (Perin et al., 2004; Schachinger et al., 2004; review, Muller et al, 2005) , it was recently reported that improvements in cardiac function were only temporary (Meyer et al., 2006) . Moreover, because the basis for improved recovery is unlikely mediated by re-muscularization of damaged myocardium, the need to evaluate cells capable of differentiating into contractile tissue has been emphasized (review, .
By contrast with adult stem cells, the robust ability of embryonic stem cells (ESCs) to differentiate into cardiac myocytes both in vitro (Rudy-Reil & Lough, 2004; Kanno et al., 2004) and in vivo (Hodgson et al., 2004) warrants their evaluation as therapeutic agents. In this regard, recent reports have indicated that transplanted pluripotent ESCs confer modest functional improvement of infarcted myocardium in mouse (Behfar et al., 2002; Hodgson et al., 2004; Singla et al., 2006; Kofidis et al., 2005) and rat (Min et al., 2002; models. Although monitoring of differentiated ESC outcomes has indicated that pluripotent donor cells can differentiate into cell types present in the adult heart (Behfar et al., 2002; Hodgson et al., 2004; Singla et al., 2006) , the reliance on fluorescent signals to establish identities of the transplanted cells has been questioned because infarcted myocardium is auto-fluorescent (reviews, Laflamme & Murry, 2005; Terman & Brunk, 2005) . To circumvent this potential problem we developed two lines of ESCs that enable lacZ-based histochemical distinction between (i) donor cells that constitutively express the elongation factor (EF) promoter and (ii) donor cells which differentiate into cardiomyocytes, per cardiac-specific expression of the α-myosin heavy chain (α-MHC) promoter.
We have used these ESC lines to evaluate cardiac regeneration in a mouse model of myocardial infarction in which the left anterior descending (LAD) and the first proximal branch of the left circumflex (LCX) arteries are permanently ligated followed one hour later by injection of a relatively low number (50,000) of pluripotent ESCs. Eight weeks later, donor cells were identified in ischemic areas, only, based on expression of constitutively-expressed β-galactosidase. Evidence that at least some of the transplanted cells differentiated into cardiomyocytes was indicated by expression of α-MHC-dependent β-galactosidase. Although ESC-derived teratomas developed in the pericardium of 21% of the transplanted hearts, the absence of engrafted donor cells within the myocardium of these hearts suggested that infarcted myocardium does not support tumor growth. Echocardiographic evaluation of infarcted/ transplanted hearts that did not contain tumors revealed modest albeit significant improvements in several parameters of cardiac function including ejection fraction (EF), circumferential fiber shortening velocity (VCF) and peak mitral bloodflow velocity (peak-E). These findings add to the weight of evidence that pluripotent ESCs, even in small numbers, can confer significant functional improvement to infarcted myocardium, and indicate that this environment can support the differentiation of pluripotent ESCs into cardiomyocytes, a requirement for myocardial re-muscularization.
Methods

Genetically-Engineered ESCs
The line of murine embryonic stem cells used in these experiments, R1 ES cells, was prepared from a male E3.5 blastocyst resultant from crossing 129X1/SvJ and 129S1 mice. To create the ES-R1-F3 subline (hereafter F3 cells), the proximal promoter and first exon of the X-linked endogenous HPRT gene were replaced with a neomycin-resistance cassette, causing this cell line to be highly sensitive to HAT treatment (Misra et al., 2001 ). F3 cells can be rescued by homologous recombination with an HPRT targeting vector containing the missing HPRT gene sequences, thereby conferring resistance to HAT treatment and effectively selecting for singlecopy transgenic ESCs. Construction of the expression cassette containing the α-MHC promoter (kindly provided by Dr. Jeffrey Robbins, Cincinnati Children's Hospital Medical Center; Gulick et al., 1991) upstream of β-galactosidase cDNA was described previously (Misra et al., 2001 ); this construct is hereafter referred to as α-MHC-lacZ. The expression cassette containing the elongation factor (EF) promoter was kindly provided by Dr. Sangmi Chung, Harvard University; this promoter is constitutively expressed in pluripotent and differentiated ESCs (Chung et al., 2002) . To prepare this cassette, the ~1 kbp EF promoter was removed from pEFhrGFP (Chung et al., 2002) by Not1/Nsi1 digestion, blunted, and ligated into a shuttle vector, pMB105lacZ (Misra et al., 2001) , which contains a nuclear β-galactosidase cDNA (from pLacF plasmid) and 3'-UTR. The resultant cassette, hereafter termed EF-lacZ, was sub-cloned into the Not1 site of pMP8NEB-lacZ, from which 100 µg were purified, linearized with restriction endonuclease PME1 and re-suspended along with 1.5 × 10 8 F3-ESCs in 3.1 ml growth medium. The mixture (600 µl) was electroporated in 4 mm gap cuvettes (BioRad) at 250 Volts/500µf/ r8 using a BTX Electro Cell Manipulator 600. The F3-ESCs were plated on mouse embryonic fibroblast (MEF) feeders in standard culture medium containing LIF (below). HAT (Sigma) selection was started two days after electroporation and 10-20 colonies of putative F3-ESC-EF-lacZ cells were isolated within 10-16 days. Transgenic cell lines were genotyped by PCR amplification of the lacZ gene using the primer pair 5'-CACCGATCGCCCTTCCCAACAGTT-3' and 5'-TGCCGCTCATCCGCCACATA-3'. Accuracy of targeting into the HPRT locus was determined by Southern Blotting (Misra et al., 2001 ).
Preparation of F3 cells for Injection
All cell culture components were purchased from Specialty Media (Phillipsburg NJ) except where indicated. To prepare F3 cells for injection, aliquots were expanded without feeders in ES cell culture medium consisting of DMEM supplemented with 1 mM sodium pyruvate, 0.1 M non-essential amino acids, 2 mM glutamine, 0.2 mM β-mercaptoethanol, 1x pen/strep antiobiotics, pre-tested 15% fetal calf serum (FCS; Hyclone) and leukocyte inhibitory factor (LIF) at a concentration (i.e. 1x LIF) that was empirically determined to preserve pluripotency of ESCs for a minimum of four population doublings. F3 cells were harvested with trypsin/ EDTA to form a cell suspension that was counted with a hemocytometer. Cells for intra-cardiac injection were washed by gentle centrifugation and re-suspended in ES medium (without FCS or LIF) and adjusted to a final concentration of 50,000 cells/10 µl.
Myocardial Infarction and ESC Transplantation
To prepare for infarction, 10-14 week-old male C57BL/6 mice were anesthetized with sodium pentobarbital (100 mg/kg i.p.) and placed on a warm heating pad to maintain body temperature at 37 °C. A PE-60 polyethylene tube was inserted into the trachea and connected to a mouse ventilator (Hugo Sachs Elektronic Model 845, Germany). Mice were respirated (tidal volume = 225 µL; rate -100 strokes/min) with 100% oxygen to maintain blood gases within normal physiological limits. An electrocardiogram was obtained with needle electrodes using the limb lead II configuration. A thoracotomy was performed at the fourth left intercostal space to expose the heart, the pericardium was opened, and an 8-0 nylon suture was ligated around the left anterior descending (LAD) coronary artery ~3 mm from the tip of the normally positioned left atrium with the aid of a dissecting microscope. A second ligature was placed around the first proximal branch of the left circumflex (LCX) coronary artery supplying the anterior/lateral wall of the heart. Experimental mice were injected with either 50 × 10 3 α-MHC-lacZ cells or 50 × 10 3 EF-lacZ cells, suspended in 10 µl ES medium without FCS or LIF. In both cases, control mice received 10 µl ES medium, only. And, ten sham-operated mice were prepared identical to the experimental mice described in Table 2 , except that the ligatures in these mice were not tightened (i.e. the mice were not subjected to ischemia) and they did not receive cells or medium. The injections were performed one hour after ligation, using a Hamilton syringe, to an area along the inferior border of the infarcted area. After injection, the chest wall was closed with a 7-0 polypropylene suture with one layer through the chest wall and muscle, and a second layer through the skin and subcutaneous tissue. Mice were removed from the ventilator and kept in a warm chamber supplied with 100% oxygen. The endotracheal tube was withdrawn after 30 minutes.
Echocardiography
Echocardiography of infarcted mice injected with EF-lacZ cells and parallel ES medium controls was performed at the University of Wisconsin Department of Medicine Cardiovascular Physiology Core facility on mice lightly anesthetized with ketamine chloride (35 mg/kg i.p.), using a Sonos 5500 echocardiograph (Agilent Technologies, Palo Alto, CA) equipped with a 15-MHz pediatric transducer. Echocardiography of infarcted mice injected with α-MHC-lacZ cells (and parallel ES medium controls) was performed at the Medical College of Wisconsin Cardiovascular Center core facility on mice anesthetized with 1% isoflurane using a VisualSonics Vevo 770 high-frequency ultrasound rodent imaging system equipped with a 30-MHz mouse probe designed for cardiac imaging (VS-RMV-707). In both instances parasternal short-axis, long-axis and apical views were recorded. The parasternal short-axis view was used to measure anteroposterior internal diameter (D), anterior wall thickness (AW), and posterior wall thickness (PW) at end-diastole (D) and end-systole (S) at the mid-papillary level. The apical position was used to monitor inflow through the mitral valve and outflow through the aortic valve by pulsed Doppler to measure isovolumic relaxation, isovolumic contraction and ejection times. Left ventricular systolic function was assessed by fractional shortening (FS, % = [(LVDd-LVDs)/LVEDd]*100), mean velocity of circumferential fiber shortening (V cf , circumferences/second = FS/ejection time), and the myocardial performance index (MPI = [isovolumic contraction time+isovolumic relaxation time]/ejection time).
Histology
After nine weeks, mice were anesthetized with sodium pentobarbital (100 mg/kg i.p.) and hearts were rapidly exposed and perfused with ice-cold cardioplegic solution (25 mM KCl/5% dextrose) to arrest during diastolic relaxation. Hearts were rapidly removed, atria with AV valves were excised, prior to placing ventricles in 0.25% glutaraldehyde fixative for 30 minutes. X-gal staining was performed as previously described (Nelson et al., 2004) , overnight at 37°C
. After photographing intact ventricles, these were transversely sectioned through the plane at the site of ligation and embedded by rapid freezing in OCT medium for subsequent sectioning at 7-10 micrometer thickness to detect lacZ+ cells. Parallel sections were stained with Masson's Trichrome (cat. no. HT15; Sigma-Aldrich, St. Louis, MO) to detect areas of collagen deposition.
Results
Derivation of ESC Lines that Express β-Galactosidase in Constitutive & in Tissue-Specific Fashion
To identify transplanted donor cells we generated two lines of ESCs, termed EF-lacZ and α-MHC-lacZ cells, that respectively express nuclear β-galactosidase under control of the constitutive EF and cardiac-specific α-MHC promoters. Either promoter was cloned upstream of the lacZ expression cassette, subcloned into the mouse HPRT targeting vector, and electroporated for site-specific homologous recombination with the HPRT locus in R1-derived F3 ES cells. These procedures are schematically summarized in Figure 1A . This targeting strategy enables highly efficient screening in HAT medium, resulting in greater than 95% correctly targeted clones that contain a single, non-epigenetically inserted transgene (Misra et al., 2001; Nelson et al., 2004) . By avoiding random integration of multiple gene copies, the resulting ESCs are genetically identical to the parental cells except for the transgene. Figure  1B demonstrates high levels of β-galactosidase in the EF-lacZ line, which expresses this marker regardless of differentiative state, in cultured pluripotent ESCs. And, Figure 1C shows that the α-MHC-lacZ construct is exclusively expressed in the hearts of embryos prepared from these cells by tetraploid aggregation, per the technique previously described (Misra et al., 2001) ; note that because tetraploid aggregation produces embryos that are completely derived from ESCs, all cells within the embryo contain the same genome.
Transplantation & Survival of EF-lacZ & α-MHC-lacZ Cells in Acutely Infarcted Mouse Myocardium
To assess whether small numbers of pluripotent ESCs can be used in a mouse model of myocardial infarction, conditions were established that permit reproducible, large infarctions without causing high mortality. A double-ligation procedure was utilized; distal ligation of the left anterior descending (LAD) artery and a branch of the left circumflex (LCX) artery (Fig.  1D ) caused infarction of nearly the entire anterior and lateral walls of the left ventricle (Fig.  1E ). Although this two-vessel ligation caused ECG changes within 60 min ( Figure 1D ) and significant thinning of the anterior/lateral free wall ( Figure 1E ), the peri-operative mortality rate was only 11%, followed by a 95% survival rate after nine weeks. One hour after ligation, a single injection of 10 µl containing 50,000 ESCs, or vehicle only, was introduced to the infarction site as illustrated in Figure 1E .
Eight weeks after injecting either cell-line, mice were subjected to echocardiography and hearts were histochemically reacted with X-gal to detect transplanted ESCs (Fig. 2) . Among 12 hearts injected with EF-LacZ cells, 11 exhibited β-gal positive cells that were essentially homogeneously distributed throughout the scar tissue; β-gal positive cells were not detected outside of the infarcted area, which is indicated by the broken line in Figure 2A . The single heart that did not exhibit β-gal positive cells in the myocardium exhibited a large (5 mm diameter) teratoma that appeared to be confined to the pericardial sac ( Figure 2C ). Figure 2B shows sections from the ischemic area of X-gal stained hearts that had been infarcted and injected with medium only (left panels) or EF-lacZ cells (right panels); in the latter, β-gal positive transplanted cells detected by X-gal staining were accompanied by a relatively extensive deposition of collagen fibers as revealed by Masson trichrome staining. Figure 2D shows a section removed from a similar location of an infarcted, X-gal reacted heart that had been injected with α-MHC-LacZ cells; in this instance β-gal expression indicates differentiation into cardiomyocytes (Misra et al., 2001) . Hearts injected with MHC-LacZ cells also exhibited tumor formation, at an incidence of four in 12; hence the overall tumor incidence using both cell lines was five in 24, an occurrence rate of ~21%.
Although it was not possible to enumerate the relative numbers of β-gal positive cells from each cell line in this study, results indicate that ischemic myocardium can support the survival of transplanted pluripotent ESCs ( Fig. 2A, 2B) , and that some of these differentiate into cardiomyocytes (Fig. 2D) . Moreover, because ESC-derived tumors have been observed only in the pericardial sac (Fig. 2C) , not in healthy or ischemic myocardium, the possibility is suggested that growth factors and/or cytokines limited to the latter environment may nurture the differentiation of ESCs without promoting proliferation signals that lead to unregulated cellular growth.
Transplantation of only 50,000 Pluripotent EF-lacZ or α-MHC-lacZ Cells during Acute Myocardial Infarction Improves Cardiac Function
Cardiac function in animals injected with medium only (controls) or 50,000 cells of either ESC line one hour after infarction was assessed by echocardiography eight weeks later. Table 1 and  Table 2 present summaries of the echocardiographic results using EF-lacZ and α-MHC-lacZ cells, respectively. Using EF-lacZ cells (Table 1) , although there were no differences in left ventricular dimensions during diastole (AWd, PWd, and LVDd) between the two experimental groups, mice transplanted with EF-lacZ ESCs exhibited significant improvements in indices of systolic function including LVDs, fractional shortening and velocity of circumferential shortening. Moreover, the myocardial performance index (MPI), a Doppler-derived index of global left ventricular function (Broberg et al., 2003) , was increased to borderline statistical significance (P=0.064). Representative M-mode echocardiograms of a vehicle-treated mouse heart and a heart injected with EF-lacZ cells are shown in Figure 3 , indicating the improvement in anterior wall motion.
Infarcted hearts injected with 50,000 α-MHC-lacZ cells exhibited statistically significant improvements in the same parameters after eight weeks (Table 2 ); in addition, other parameters that were not statistically improved in EF-lacZ-injected hearts were improved in hearts injected with α-MHC-lacZ-injected cells, including anterior wall diameter (diastole), the peak velocity of blood flow through the mitral valve (peak E) and the isovolumic relaxation time (IVRT). Echocardiography performed on the same animals only four weeks after infarction/ transplantation indicated that these functional parameters were improved by that time (fourweek data are shown only for ejection fraction; Fig. 3C ). The extent of functional improvement in selected parameters mediated by EF-lacZ and α-MHC-lacZ cells is compared in Figure 3D . Hence, cell therapy with α-MHC-lacZ ESCs confers functional improvements that are detectable by four weeks and are maintained throughout at least the next four weeks.
Discussion
In these experiments we modified two ESC lines to express a single-copy β-galactosidase transgene, activated by either a constitutive promoter (EF-lacZ) or by a cardiac-specific promoter (α-MHC-lacZ). Using this approach we were able to monitor the fate of transplanted cells via histochemistry, rather than fluorescent markers, thereby avoiding the possibility of confounding false-positive signals that are reportedly caused by auto-fluorescence generated by ischemic myocardium (Terman & Brunk, 2005) . Because the expression of β-galactosidase reveals the presence of all injected EF-lacZ donor cells regardless of their differentiative state, while the expression of β-galactosidase by transplanted α-MHC-lacZ cells indicates their differentiation into cardiac myocytes, we were able to respectively distinguish generic donor cells from donor cells that actually differentiated into cardiomyocytes. These results indicate that transplanted, pluripotent ESCs can survive in ischemic myocardium, and that at least some of these are able to differentiate into cardiomyocytes, which are theoretically capable of contracting (Rudy-Reil & Lough, 2004) . Using the approach employed in this study, coupled with refinements in histological processing, quantitative assessment of the percentages of EFlacZ donor cells that differentiate into α-MHC-lacZ positive cardiomyocytes should be possible.
Our observations that pluripotent ESCs engraft and survive only within ischemic myocardium imply that these transplanted cells cannot migrate into areas of viable myocardium, and that the ischemic environment uniquely provides trophic factors sufficient for the survival and differentiation of pluripotent ESCs. Regarding the observation that ESC-derived tumors occurred only in the pericardial sac, we speculate that this resulted from inadvertent injection of ESCs into this area, wherein pluripotent cells, in the absence of cardio-inductive molecules in the infarcted environment (Behfar et al., 2002) , may undergo teratogenesis. This interpretation is consistent with findings recently reported by Behfar et al. (2005) , who established that a therapeutic load of as many as 10 5 ESCs (i.e. 10 3 ESCs/mg heart weight) should not cause tumorigenesis.
That significant functional recovery of mouse myocardium is mediated by either pluripotent ESC line (Table 1-Table 2 ) confirms previous findings using relatively large numbers of pluripotent ESCs in this small animal model (Hodgson et al., 2004, 3 × 10 5 ESCs; Kofidis et al., 2005, 10 6 ESCs), as well as very recent findings in which low numbers of transplanted ESCs similar to those reported here were observed to confer functional benefit (Singla et al., 2006; 3 × 10 4 ESCs). In comparing results in these Tables it is noted that because different drugs were used to induce mild anesthesia during echocardiography (ketamine for Table 1 and isoflurane, which is more cardio-depressive, in Table 2 ) it is speculated that this is the major cause of baseline differences in these data. In particular, the extent of improved fractional shortening, a parameter that approximates ejection fraction, reported in the cited studies is similar to the extent of improvement reported here. The aggregate of these findings provide strong evidence that small numbers of ESCs can confer functional benefit, which should enhance cell therapy paradigms using pre-differentiated ESCs, pure cohorts of which are obtainable in relatively small numbers. This is important in view of our observations that at least some of the transplanted pluripotent ESCs differentiate into cardiomyocytes, suggesting that improved function, at least in part, results from de novo cardiomyogenesis.
Although these studies indicate that pluripotent ESCs confer improved function after transplantation, normative values were not re-established. Although the benefit of transplanting α-MHC-lacZ cells was observed after four weeks (animals transplanted with EF-lacZ cells were not echocardiographed at that time) and was stable through at least eight weeks, the extent of improvement between these two time points did not differ for any parameter. Nonetheless, whether infarcted hearts transplanted with pluripotent ESCs continue to improve toward normative values during longer-term recovery must be investigated. Moreover, the extent to which transplanted pluripotent ESCs differentiate and integrate into healthy myocardium, as well as whether pre-differentiation of donor ESCs confers improvements in these parameters as well as function, is also being investigated. lacZ cells containing a β-gal+ tumor located between epicardium and pericardium. This mass, which is magnified in the lower part of panel C, was not incorporated into the myocardium. The blue color indicates the origin of cells in this tumor from the EF-lacZ cells; however, whether they are cardiomyocytes cannot be discerned. Bar = 500 µm. (D) Cross-section of Xgal reacted whole mount heart that had been infarcted and injected with α-MHC-lacZ cells; the blue color denotes de novo cardiogenesis. Bar = 200 µm. 
